Literature DB >> 9059350

Topoisomerase II alpha mRNA and tumour cell proliferation in non-Hodgkin's lymphoma.

A Lohri1, J Reuter, F Gudat, R Herrmann.   

Abstract

AIMS: To elucidate potential mechanisms of drug resistance, levels of topoisomerase II alpha mRNA, a target for cytostatic drugs, were measured in cryopreserved tumour tissue from 36 patients with non-Hodgkin's lymphoma. To evaluate the potential association between topoisomerase II alpha and cell proliferation, Ki-67 immunostaining was also assessed.
METHODS: The study population comprised 13 patients with low grade and 20 with high grade non-Hodgkin's lymphoma. Three patients had recurrent disease. Topoisomerase II alpha mRNA was quantitated by using reverse transcription polymerase chain reaction (RT-PCR) and the PCR product measured by using HPLC. The MIB-1 monoclonal antibody was used for Ki-67 immunostaining.
RESULTS: Levels of topoisomerase II alpha mRNA correlated strongly with the Ki-67 labelling index and were higher in high grade than in low grade lymphomas. Patients in complete clinical remission of high grade lymphoma had a higher Ki-67 labelling index and tended to have higher topoisomerase II alpha mRNA levels.
CONCLUSIONS: Although topoisomerase II alpha mRNA levels may be indicative of sensitivity to drugs, it is more likely that they reflect the proliferation status of the cell, which in turn involves a large number of additional molecular systems that influence response to treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9059350      PMCID: PMC499706          DOI: 10.1136/jcp.50.1.22

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  21 in total

1.  Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies.

Authors:  F Boege; A Andersen; S Jensen; R Zeidler; H Kreipe
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

2.  Nonradioactive quantification of mdr1 mRNA by polymerase chain reaction amplification coupled with HPLC.

Authors:  B van Hille; A Lohri; J Reuter; R Herrmann
Journal:  Clin Chem       Date:  1995-08       Impact factor: 8.327

3.  Molecular structure of the human cytoplasmic beta-actin gene: interspecies homology of sequences in the introns.

Authors:  S Nakajima-Iijima; H Hamada; P Reddy; T Kakunaga
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

4.  Messenger RNA expression of resistance factors and their correlation to the proliferative activity in childhood acute lymphoblastic leukemia.

Authors:  G Stammler; A Sauerbrey; M Volm
Journal:  Cancer Lett       Date:  1995-02-10       Impact factor: 8.679

5.  Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial.

Authors:  T P Miller; T M Grogan; S Dahlberg; C M Spier; R M Braziel; P M Banks; K Foucar; C R Kjeldsberg; N Levy; B N Nathwani
Journal:  Blood       Date:  1994-03-15       Impact factor: 22.113

6.  Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line.

Authors:  C D Evans; S E Mirski; M K Danks; S P Cole
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

Review 8.  Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group.

Authors:  G Brittinger; H Bartels; H Common; E Dühmke; H H Fülle; U Gunzer; T Gyenes; R Heinz; E König; P Meusers
Journal:  Hematol Oncol       Date:  1984 Jul-Sep       Impact factor: 5.271

9.  Topoisomerase II alpha expression in acute myeloid leukaemia and its relationship to clinical outcome.

Authors:  S L McKenna; R R West; J A Whittaker; R A Padua; J A Holmes
Journal:  Leukemia       Date:  1994-09       Impact factor: 11.528

10.  High mdr1- and mrp-, but low topoisomerase II alpha-gene expression in B-cell chronic lymphocytic leukaemias.

Authors:  J Beck; D Niethammer; V Gekeler
Journal:  Cancer Lett       Date:  1994-10-28       Impact factor: 8.679

View more
  4 in total

1.  Topoisomerase II alpha and II beta expression in childhood acute lymphoblastic leukaemia: relation to prognostic factors and clinical outcome.

Authors:  A J Lodge; A G Hall; M M Reid; G G McIntosh; M Steward; J J Anderson; C H Horne; B Angus
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

2.  High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy.

Authors:  Yong Won Choi; Mi Sun Ahn; Jin-Hyuk Choi; Hyun Woo Lee; Seok Yun Kang; Seong Hyun Jeong; Joon Seong Park; Jae Ho Han; Jang-Hee Kim; Seung Soo Sheen
Journal:  Int J Hematol       Date:  2015-11-19       Impact factor: 2.490

3.  Cyclins D1 and D3 and topoisomerase II alpha in inactive pituitary adenomas.

Authors:  W Saeger; S Schreiber; D K Lüdecke
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

4.  A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma.

Authors:  Faezeh Ajorloo; Mohammad Vaezi; Alireza Saadat; Seyed Reza Safaee; Behrouz Gharib; Mostafa Ghanei; Seyed Davar Siadat; Farzam Vaziri; Abolfazl Fateh; Mehrdad Pazhouhandeh; Behrouz Vaziri; Reza Moazemi; Fereidoun Mahboudi; Fatemeh Rahimi Jamnani
Journal:  PLoS One       Date:  2017-09-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.